Related Experiment Videos
Infants younger than 1 year of age with rhabdomyosarcoma
Insights
Infants under one year old diagnosed with rhabdomyosarcoma showed distinct tumor characteristics and treatment challenges. However, age is not a significant prognostic factor for rhabdomyosarcoma survival.
Area of Science:
- Pediatric Oncology
- Cancer Research
- Clinical Trials
Background:
- Rhabdomyosarcoma is a rare childhood cancer.
- Infants (under 1 year) represent a small but distinct subgroup of patients.
- Understanding age-specific differences is crucial for treatment optimization.
Purpose of the Study:
- To compare clinical characteristics, pathology, and outcomes of infants (<1 year) versus older children (1-20 years) with rhabdomyosarcoma.
- To evaluate the prognostic significance of age in rhabdomyosarcoma.
Main Methods:
- Analysis of data from 1561 patients registered in the Intergroup Rhabdomyosarcoma Study (IRS) up to May 1983.
- Comparison of demographic, clinical, pathological, and survival data between infants and older children.
- Review of treatment adherence and toxicity in different age groups.
Main Results:
- Infants had a higher frequency of undifferentiated sarcoma (18% vs 7%) and botryoid pathology (10% vs 4%).
- Infants presented more frequently with bladder-prostate-vagina tumors (24% vs 10%).
- Infants received less chemotherapy/radiation and experienced more toxicity, yet overall survival was similar to older children.
Conclusions:
- While infants exhibit unique rhabdomyosarcoma characteristics and treatment issues, age is not a significant prognostic factor.
- Unlike Wilms' tumor or neuroblastoma, younger age does not confer a survival advantage in rhabdomyosarcoma.
- Further research into age-specific management strategies for rhabdomyosarcoma is warranted.
Abstract:
Of a total of 1561 patients registered in the Intergroup Rhabdomyosarcoma Study (IRS) as of May 1983, 78 patients (5%) were younger than 1 year of age. These infants did not differ from the older children (1-20 years of age) in male/female ratio, clinical grouping, or survival rates. Infants younger than 1 year of age had a significantly greater frequency of undifferentiated sarcoma, 18% versus 7% in older children (P less than 0.005). Infants also had a significantly greater proportion of cancers with botryoid pathology, 10% versus 4% in older children (P less than 0.005). When reviewed by the newly proposed IRS cytopathologic classification, there was no difference in pathologic types between the two age groups. Infants younger than 1 year of age had a higher rate of bladder-prostate-vagina primary tumor sites than older children, 24% versus 10% (P less than 0.05). In addition, infants tended to receive less of the prescribed doses of chemotherapy and radiation therapy than older children, and to develop more toxicity to treatment than older children. Despite these differences, the overall survival curve for the two age groups appears to be similar. In contrast to Wilms' tumor and neuroblastoma, in which age (less than 1 year) is a favorable prognostic factor, age does not appear to be an important prognostic factor in rhabdomyosarcoma.